8-K: Solo Brands Appeals NYSE Delisting, Gains Shareholder Approval for Officer Exculpation and Reverse Stock Split

Solo Brands, Inc. is appealing its NYSE delisting and trading suspension, while shareholders approved key corporate governance changes including officer exculpation and a potential reverse stock split.

Summary

• Solo Brands, Inc.'s Class A common stock has been suspended from trading on the New York Stock Exchange (NYSE) since April 22, 2025, and is currently quoted on the OTC Pink Market under the symbol DTCB.
• The company formally appealed the NYSE's April 22, 2025, decision to delist its stock due to 'abnormally low price levels'.
• On May 29, 2025, the NYSE further notified the company of non-compliance with Rule 802.01D, as its average global market capitalization over a consecutive 30-trading day period fell below $15,000,000.
• During the appeal period, the Class A common stock remains listed on the NYSE, but trading continues to be suspended, with no guarantee of successful appeal or relisting.
• At its Annual Meeting on May 23, 2025, shareholders approved an amendment to the company's Certificate of Incorporation to provide for the exculpation of officers from monetary damages for breaches of fiduciary duty, to the fullest extent permitted by Delaware law.
• Shareholders also approved an amendment to effect a reverse stock split of Class A and Class B common stock at a ratio ranging from 1-for-10 to 1-for-100, at the Board of Directors' discretion.
• Additionally, three Class I directors (John P. Larson, Andrea K. Tarbox, and Elisabeth Vanzura) were elected to serve until the 2028 annual meeting, and the appointment of BDO USA, P.C. as the independent registered public accounting firm for 2025 was ratified.

Sentiment

Score: 2

Explanation: The company is facing delisting from the NYSE and its stock has been suspended from trading, moving to a less liquid market. While management is appealing and shareholders approved measures like a potential reverse stock split, the immediate implications for investors are highly negative due to reduced liquidity and potential further price depression.

Positives

• Shareholders approved the exculpation of officers from certain fiduciary duty breaches, which may provide greater protection for management and aid in officer retention.
• Shareholders approved the Board's discretion to implement a reverse stock split, a potential tool to regain NYSE compliance regarding minimum share price or market capitalization, if the appeal is successful.
• The company is actively appealing the delisting decision, indicating efforts to maintain its NYSE listing.
• Key directors were re-elected and the auditor was ratified, indicating continuity in governance and financial oversight.

Negatives

• The company's Class A common stock has been suspended from trading on the NYSE since April 22, 2025, and is now quoted on the significantly more limited and less liquid OTC Pink Market.
• The NYSE initiated delisting proceedings due to 'abnormally low price levels' and subsequently cited non-compliance with the $15,000,000 average global market capitalization rule.
• Trading on the OTC Pink Market is likely to result in a less liquid market and could further depress the trading price of the Class A common stock.
• There is no guarantee that the company will be successful in its appeal to resume trading or remain listed on the NYSE.

Risks

• Delisting Risk: The company faces the significant risk of permanent delisting from the NYSE, which would severely limit its access to capital markets and investor visibility.
• Liquidity Risk: Trading on the OTC Pink Market is significantly less liquid than the NYSE, making it harder for shareholders to buy or sell shares and potentially leading to wider bid-ask spreads.
• Price Depression Risk: The move to the OTC Pink Market and the ongoing delisting uncertainty could further depress the trading price of the Class A common stock.
• Reputational Risk: Delisting from a major exchange like the NYSE can damage the company's reputation among investors, customers, and suppliers.
• Uncertainty of Appeal: There is no guarantee that the company's appeal to the NYSE will be successful, leaving its listing status uncertain.

Future Outlook

The company is actively appealing the NYSE's delisting decision, with the Class A common stock remaining listed but suspended from trading during this period. There is no guarantee of success in resuming trading or remaining listed on the NYSE. Shareholders have approved a potential reverse stock split, which the Board may implement at its discretion, possibly as a measure to regain compliance with listing standards if the appeal is successful.

Management Comments

• "During the appeal period, our Class A common stock remains listed on the NYSE, though trading in the Class A common stock is suspended."
• "There is no guarantee that the Company will be successful in its efforts to resume trading or remain listed on the NYSE."
• "The OTC Pink Market is a significantly more limited market than the NYSE, and quotation on the OTC Pink Market likely results in a less liquid market for existing and potential holders of the Class A Common Stock and could further depress the trading price of the Class A Common Stock."
• Chris Blevins, Interim General Counsel and Secretary, signed the report.

Industry Context

The delisting of Solo Brands, Inc. from the NYSE and its subsequent quotation on the OTC Pink Market highlights the challenges faced by smaller-cap companies in maintaining compliance with major exchange listing standards, particularly during periods of market volatility or operational difficulties. Such events can significantly impact investor confidence and access to capital, often leading to reduced liquidity and depressed share prices. The approval of officer exculpation is a common corporate governance trend, especially in Delaware, aimed at protecting officers from certain liabilities, which can be seen as a measure to attract and retain talent, though it may be viewed differently by shareholder advocacy groups. The proposed reverse stock split is a typical strategy employed by companies to increase their share price to meet minimum listing requirements or improve market perception, often following a period of significant stock price decline.

Comparison to Industry Standards

• Delisting from a major exchange like the NYSE is generally considered a significant negative event, contrasting sharply with the standards of well-capitalized, actively traded public companies.
• The company's average global market capitalization falling below $15,000,000 is well below the typical market capitalization of companies listed on the NYSE, which often require minimums in the hundreds of millions or billions of dollars for sustained listing.
• The move to the OTC Pink Market places Solo Brands in a less regulated and less liquid trading environment, unlike its peers that maintain listings on major exchanges such as the NYSE or NASDAQ, which offer greater transparency and investor protections.
• The approval of officer exculpation aligns with a growing trend in Delaware corporate law, where many companies are adopting similar provisions to protect their officers, a practice that is becoming a standard for corporate governance in the state.
• The proposed reverse stock split is a common mechanism used by companies across various industries when their stock price falls below exchange minimums, aiming to consolidate shares and increase per-share value, a strategy also seen in other companies facing similar listing challenges.

Management Changes

Corporate Governance

Legal Proceedings

• The company is engaged in an appeal process with the NYSE regarding the determination to delist its Class A common stock, following initial suspension due to 'abnormally low price levels' and subsequent non-compliance with the $15,000,000 average global market capitalization rule. This is a regulatory matter rather than a traditional legal proceeding.

Stakeholder Impact

• Shareholders: Face significantly reduced liquidity and potential further price depreciation due to trading on the OTC Pink Market and the uncertainty of NYSE relisting. The approved reverse stock split could impact share count and per-share price. Officer exculpation may limit recourse for certain fiduciary breaches.
• Employees: Potential impact on morale and stability due to the company's precarious listing status and associated financial uncertainty.
• Customers/Suppliers: Indirect impact from potential reputational damage or financial instability, though not directly addressed in the filing.
• Creditors: Potential impact on creditworthiness and access to financing due to the company's delisting status and low market capitalization.

Next Steps

• Continuation of the appeal process with the NYSE regarding the delisting determination.
• Potential implementation of a reverse stock split by the Board of Directors, at their discretion, at a ratio between 1-for-10 and 1-for-100.
• Ongoing trading of Class A common stock on the OTC Pink Market under the symbol DTCB.

Key Dates

Recommendation

Keywords

Solo Brands, DTC, NYSE, delisting, OTC Pink Market, stock suspension, market capitalization, officer exculpation, reverse stock split, corporate governance, shareholder meeting, 8-K filing, financial reporting, public company